Detalhe da pesquisa
1.
A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway.
Skin Pharmacol Physiol
; 34(6): 307-316, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34058738
2.
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
N Engl J Med
; 375(3): 240-6, 2016 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27468060
3.
Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
Gastroenterology
; 153(5): 1240-1250.e2, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28760384
4.
Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
Gastroenterology
; 151(1): 87-96.e6, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27055601
5.
Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
Clin Gastroenterol Hepatol
; 13(13): 2312-9.e1, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26001337
6.
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Cell Metab
; 7(1): 68-78, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18177726
7.
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
J Hepatol
; 58(3): 479-87, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23183529
8.
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Hepatology
; 56(2): 567-75, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22619063
9.
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Br J Clin Pharmacol
; 75(5): 1240-54, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23013236
10.
Pharmacokinetic-pharmacodynamic studies of the 11ß-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Br J Clin Pharmacol
; 76(6): 917-31, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23594227
11.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Cell Metab
; 4(4): 275-82, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17011500
12.
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Br J Clin Pharmacol
; 71(3): 429-36, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21284702
13.
Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Clin Drug Investig
; 30(12): 855-66, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20923244
14.
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
Antimicrob Agents Chemother
; 53(7): 2752-5, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19398643
15.
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Antimicrob Agents Chemother
; 53(7): 2852-6, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19433563
16.
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Lancet
; 372(9653): 1881-1893, 2008 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-19012954
17.
The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.
J Clin Pharmacol
; 49(7): 807-15, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19443681
18.
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
J Clin Pharmacol
; 49(1): 80-7, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19004846
19.
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
J Clin Pharmacol
; 49(8): 937-46, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19602719
20.
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
J Clin Pharmacol
; 49(7): 856-64, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19491335